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ABSTRACT
The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric
determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with
bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger
cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body
mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and
overall survival were assessed for the overall study population and subgroups defined upon molecular
subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on
clinical benefit rates in the overall study sample and in the luminal cancer subset (p D 0.12 and p D 0.79,
respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass
index 25 (p D 0.03). In the overall study sample, body mass index did no impact progression free or
overall survival (p D 0.33 and p D 0.67, respectively). Conversely, in triple negative patients, progression
free survival was significantly longer with body mass index 25 (6 vs 14 months, p D 0.04). In this subset,
overall survival was more favorable (25 vs 19 months, p D 0.02). The impact of the molecular subtype was
confirmed in multivariate models including the length of progression free survival, and number of
metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately
sized, ad hoc, prospective studies.
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Introduction
HER2-negative, metastatic breast cancer (MBC) still represents
one of the greatest challenges for medical oncologists. In these
patients, the addition of bevacizumab, a humanized monoclo-
nal antibody against VEGF-A, to first-line chemotherapy has
significantly improved the overall response rate (ORR) and
progression free survival (PFS), but has not impacted overall
survival (OS).1-3
Overall survival has been recently addressed in the TURAN-
DOT trial, a non-inferiority, randomized, phase III trial com-
paring outcomes from two approved bevacizumab-containing
regimens for first-line treatment of HER2-negative MBC. The
non-inferiority criterion was met in stratified analyses of data
from both the per protocol and ITT population, while results
from unstratified analyses were not supportive, either using a
per protocol approach, or considering the ITT population.
Data from the TURANDOT trial were also analyzed across
subgroups differing by clinically relevant variables. The inher-
ent results highlighted the role of body surface area and meno-
pausal status as substantial source of heterogeneity of
treatment effects in terms of OS.4 A further attempt of identify-
ing patients who may most benefit from bevacizumab-includ-
ing regimens was based on the evaluation of the predictive role
of plasma VEGF-A in HER2-negative MBC patients recruited
within the MERiDian trial, a blind, randomized, placebo-con-
trolled, phase III trial of bevacizumab plus paclitaxel versus
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placebo plus paclitaxel. No evidence in support of the predictive
role of pVEGF-A emerged from the MERiDian trial or from the
separately published analysis exclusively focused on the sub-
group of Japanese patients from this same study.5,6
We have previously addressed treatment outcomes in a
larger cohort of HER2-negative MBC patients treated with bev-
acizumab and paclitaxel in first-line chemotherapy.7 In light of
the evidence emerged from recent literature and within our
previously established research pipeline on the role of anthro-
pometric and metabolic determinants of treatment efficacy in
breast and ovarian cancer, we have now focused on a more
restricted subgroup of patients from the original cohort with
available data on body mass index (BMI) values at baseline
assessment.8-15 In this patient subgroup, data on several
patient- and disease-related features were also analyzed and
reinterpreted in light of the evidence emerging from the BMI-
related analysis. This study was designed and implemented
within a real world setting.4-6
Materials and methods
The present analysis was performed to explore the impact of
several patient- and disease-related features, with a particularly
specific focus on anthropometrics in a subset of patients from a
larger study of HER2-negative MBC patients treated with pacli-
taxel and bevacizumab in first-line (N:314). Formal approval
for the main and corollary studies was obtained from the insti-
tutional review boards of the coordinating and satellite centres.
A written informed consent was secured from every study par-
ticipant prior to study procedures. The study conduct was com-
pliant with the Helsinki Declaration. The methods applied were
extensively reported elsewhere.7 Briefly, in the main study,
HER2-negative MBC patients were identified and recruited
from 12 Italian cancer centres. Treatment administration was
compliant with the most updated indications and recommen-
dations. Prior to data collection and medical records retrieving,
an ad hoc database was set up and implemented. Collected data
included patient anthropometrics (weight, height, BMI), demo-
graphics, morphological and clinical characteristics referred to
the disease and patients of interest. Data on the administered
therapy/ies and related outcomes were also made available for
this study purposes. BMI values were obtained by dividing
weight in kilograms by the square of the height in meters. This
variable was addressed as categorical and a conventional cut off
value, i.e., 25, was used to define its modalities.16 In specific
regard to outcome definition and assessment, objective
response (OR) was reported using the conventional Response
Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Clinical benefit rate (CBR) was codified as the percentage of
patients with an objective response or stable disease for a mini-
mum of 6 months. Progression free survival (PFS) was defined
as the time window between treatment initiation and interrup-
tion due to disease progression or death from any cause. Over-
all survival (OS) was defined as the time from the start of
treatment to patient death from any cause.
Statistical analysis. Descriptive analyses were performed for
all the variables of interest. Medians and ranges were assessed
for continuous variables, while frequencies and percentages
were computed for categorical variables. Patient characteristics
were first described for the overall study population and then
for subgroups defined upon molecular characteristics and com-
pared across BMI strata using X2 or Fisher test, with this choice
being driven by the size and number of groups compared. Two
main subgroups were defined and distinguished on the basis of
the immunohistochemical assessment of estrogen and/or pro-
gesterone receptor/s (ER/PgR), namely, luminal cancer cases
and triple negative (TN) cancer cases. The Hazard Ratio (HR)
and 95% confidence interval (CI) were estimated for each vari-
able. The impact of specific determinants on PFS and OS was
evaluated by Cox univariate model. The Kaplan–Meier method
and the log-rank test were used to analyze and assess differen-
ces in survival. Kaplan-Meier curves were estimated for the
entire study population and for subgroups defined upon BMI
and molecular subtypes. Multivariate models included variables
testing significant at univariate analysis and/or being consid-
ered on the basis of their biological plausibility and/or literature
data. Interactions terms were added to the multivariate models
when appropriate. Significance was defined at the p0.05 level.
The SPSS software (SPSS version 21.0, SPSS Inc., Chicago, IL)
was used for all statistical evaluations.
Results
This analysis was carried out in 196 patients (N:196) diagnosed
and treated at the Institutions involved from 2008 through
2015. Patients were eligible to contribute data to our analysis if
having received at least one cycle of paclitaxel-bevacizumab
and with BMI data recorded at baseline. In Table 1, the main
patient and tumor characteristics are shown for the overall
study population. When globally considered, median age at
treatment start was 56 years (31-82). The ECOG PS assigned
was 0 in most of our patients (121; 61.7%). The most common
histology and molecular subclass were ductal invasive breast
carcinoma (166; 84.7%) and luminal breast cancer (146;
74.5%), respectively. In 134 (68.4%) patients the Ki-67%
expression was higher than 14. As concerns previous treat-
ments, neo/adjuvant chemotherapy was administered in 138
(70.4%) women, 120 (61.2%) patients received adjuvant
Table 1. Main patient and tumor characteristics (N: 196 pts).
Main patient and disease characteristics N(%)
Age in years, Median (range) 56 (31-82)
ECOG PS0 1-2 121 (61.7) 75 (38.3)
Histology Ductal Lobular Other 166 (84.7) 28 (14.3) 2
(1)
Hormone receptor status at diagnosis ER and/or PgR
positive Triple negative Unknown
146 (74.5) 43 (22.0) 7
(3.5)
KI67% 134 (68.4) 62 (31.6)
>14
14
Prior treatment Neo/adjuvant chemotherapy Adjuvant
endocrine therapy Adjuvant radiotherapy
138 (70.4) 120 (61.2)
109 (55.6)
Metastatic at diagnosis Yes No 36 (18.4) 160 (81.6)
Number of metastatic sites 12  3 67 (34.2) 62 (31.6) 67
(34.2)
Metastatic pattern Viscera yBones Other sites 119 (60.7) 23 (11.7) 54
(27.6)
N (%), number and percentage; ECOG PS, Eastern Cooperative Oncology Group
Performance Status; ER and/or PgR: Estrogen Receptor and/or Progesterone
Receptor.
yOnly bones involved.
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endocrine agents, while 109 (55.6%) patients received adjuvant
radiotherapy. Thirty-six patients (18.4%) were metastatic at
diagnosis. The metastatic spread was limited to one single site
in 67 patients (34.2%). Two 2 metastatic sites were identified in
62 women (31.6%), and 67 (34.2%) patients showed metastatic
involvement of 3 or more sites. Visceral involvement was pres-
ent in 119 (60.7%) patients, while an exclusive bone involve-
ment was represented in 23 (11.7%) patients only.
In Table 2, patient and disease characteristics were com-
pared across subgroups defined upon BMI, using a 25 cut off
value. Overall, leaner patients tended to be slightly younger
(p D 0.004) and had less commonly received neo-/adjuvant
chemotherapy or adjuvant radiotherapy (p D 0.03 and 0.009,
respectively).
As shown in Table 3, all 196 patients were evaluable for
response. No significant differences in response rates were
observed by BMI, with an overall response rate (ORR) of 64%
in patients with BMI < 25 and of 67% in patients with
BMI25 (p D 0.64). Disease control rate (DCR), defined as
CR, PR and SD lasting 6 months, was recorded in 83% of
patients with BMI<25 and 91% of patients with BMI  25
(p D 0.12). ORR did not significantly differ in patient sub-
groups defined upon molecular subtypes across BMI strata
(p D 0.99 and p D 0.49). Conversely, DCR was significantly
influenced by BMI in TN tumor cases, with better outcomes in
patients with higher BMI (p D 0.03).
When addressing survival outcomes in the overall patient
population, median PFS was 14 months (95% CI, 11–17), and
median OS was 40 months (95% CI, 28–52). Survival outcomes
were both affected by the molecular subtype (Fig. 1). At 24
months, 24.6% of patients within the luminal subtype group
were free from disease progression compared to 14.7% of
patients from the TN subgroup (p D 0.02). In regard to OS, the
estimates showed significantly better outcomes in patients from
the luminal subgroup (59 vs 32.3%, p D 0.003). No differences
in terms of PFS or OS were observed in the overall population
when analyzing data by BMI (p D 0.33 and p D 0.67, respec-
tively) (supplementary Table S1). When stratifying by molecu-
lar subtype, in the subset of patients with hormone-receptor
positive tumors, PFS and OS were independent on BMI (p D
0.85 and p D 0.41, respectively). Conversely, in the TN sub-
group, median PFS was 6 months (95% CI, 5–7) in patients
with BMI<25 and 14 months (95% CI, 10–18) in patients with
BMI (p D 0.04). Similarly, median OS was substantially lon-
ger in TN patients with BMI25 (25 vs 19 months, p D 0.02).
Survival data in patients from the TN subgroup across BMI
strata are displayed in Fig. 2. In univariate models, OS was fur-
ther affected by the number of metastatic sites (p D 0.01) and
length of PFS (p<0.0001), with more favorable outcomes in
patients with the lowest metastatic burden and PFS12 month
interval (Fig. 3A and Fig. 3B). The impact of molecular subtype,
length of PFS, and number of metastatic sites was confirmed in
multivariate models (Table 4).
Discussion
In this multicenter, observational study, we analyzed data from
196 patients with HER2-negative MBC treated with paclitaxel
and bevacizumab in first-line with available BMI data at base-
line assessment. This patient subgroup originated from a larger
cohort, whose treatment outcomes had been addressed in pre-
vious work.7 In the present manuscript, data where analyzed to
assess the impact of BMI on treatment outcomes. In the overall
patient cohort, stratification by BMI did not affect ORR or
DCR, neither did we observe any effect in the luminal type sub-
group. Conversely, in TN patients (N:43), we found
Table 2. Main patient and tumor characteristics by categories of body mass index (N: 196 pts).
Main patient and disease characteristics BMI <25 (108) N(%) BMI 25 (88) N(%) p value
Age in years, Median (range) 52 (31-76) 59 (32-82) 0.04
ECOG PS 0 1-2 63 (58.3) 45 (41.7) 58 (66.0) 30 (34.0) 0.28
Histology Ductal Lobular Other 91 (84.2) 16 (14.8) 1 (1.0) 75 (85.3) 12 (13.6) 1 (1.1) 0.96
Hormone receptor status at diagnosis ER and/or PgR positive Triple negative Unknown 83 (76.9) 20 (18.5) 5 (4.6) 63 (71.6) 23 (26.1) 2 (2.3) 0.33
KI67%>1414 69 (63.9) 39 (36.1) 65 (73.9) 23 (26.1) 0.14
Prior treatment Neo-/adjuvant chemotherapy Adjuvant endocrine therapy Adjuvant
radiotherapy
69 (63.9) 67 (62.0) 51
(47.0)
69 (78.4) 53 (60.0) 58
(66.0)
0.03 0.80
0.009
Metastatic at diagnosis Yes No 21 (19.4) 87 (80.6) 15 (17.0) 73 (83.0) 0.67
Number of metastatic sites 1 23 34 (31.5) 30 (27.8) 44
(40.7)
33 (37.5) 32 (36.4) 23
(26.1)
0.08
Metastatic pattern Viscera yBones Other 65 (60.2) 12 (11.1) 31
(28.7)
54 (61.4) 11 (12.5) 23
(26.1)
0.90
BMI, body mass index; N(%), number and percentage of patients; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ER, Estrogen Receptor; PgR, Proges-
terone Receptor.
yOnly bones involved.
Table 3. Response and disease control rate in the overall study population and subgroups defined upon molecular subtype across BMI strata (N:196).
BMI N CR/PR, N(%) p value DCR, N(%) p value
Overall population <2525 108 88 69 (64) 59 (67) 0.64 90 (83) 80 (91) 0.12
ER and/or PgR positive <2525 83 63 56 (68) 43 (68) 0.99 74 (89) 57 (91) 0.79
Triple negative <2525 20 23 11 (55) 15 (65) 0.49 12 (60) 21 (91) 0.03
BMI, body mass index; CR/PR, complete response/PR, partial response; N(%), number and percentage; DCR, disease control rate; ER and/or PgR: Estrogen Receptor and/or
Progesterone Receptor.
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significantly higher DCR associated with BMI values 25. In
the overall study sample (N:196), BMI did not influence PFS,
which was solely affected by the molecular subtype. In analysis
stratified by molecular subtype, we observed significantly more
favorable PFS and OS in TN patients with BMI 25. In the
overall study sample, a lower number of metastatic sites and
longer length of PFS were associated with significantly longer
OS.
In our study, differences by BMI did not significantly affect
treatment outcomes in the overall study sample, but did so in
analysis of DCR stratified by molecular subtype and in uni-
and multivariate Cox models of survival. Both DCR and sur-
vival outcomes appeared to be positively influenced by higher
values of BMI. Current knowledge on the role of overweight
and obesity in metastatic breast cancer is limited. Gennari and
colleagues analyzed data from 489 MBC cancer patients treated
with regimens including anthracyclines and taxanes in three
trials of first-line chemotherapy. No association was detected
between BMI and PFS or OS.17 However, the relevant differen-
ces in terms of treatment administered may at least partly
explain the inconsistency between these findings and those
from our study. As previously mentioned, in the TURANDOT
trial, treatment effects on survival showed significant differen-
ces by body surface area and menopausal status. Among
patients randomized to paclitaxel plus bevacizumab, those who
were premenopausal and with a higher body surface area (1.8
m2) exhibited the most favorable outcomes.4 Unfortunately,
data on menopausal status were not available for our study
population. When using “age in years” as a proxy of meno-
pausal status, no significant differences emerged in the overall
study population or subgroups defined upon the molecular
subtype for any of the outcomes considered (data available
upon request). Although findings from the metastatic setting
do not necessarily apply to the early setting, in discussing this
study results we are also considering evidence on BMI and
treatment outcomes from previous studies carried out in the
Figure 1. Progression-Free Survival (A) and Overall Survival (B) by molecular subtype in the overall study population (N:196).
Figure 2. Progression-Free Survival (A) and Overall Survival (B) in triple negative cancer cases (N:43) across strata of body mass index (BMI).
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neoadjuvant setting. In a phase II clinical trial exploring efficacy
and toxicity outcomes of the combined use of epirubicin and
trastuzumab in 45 HER2-positive breast cancer patients with
locally advanced operable disease, we observed better outcomes
in patients with BMI25 and whose tumors did not express
hormone receptors.10 Beyond the not negligible differences in
terms of patients characteristics, disease features and study
design, these findings are fully consistent with what reported in
the study herein presented. Conversely, in young breast cancer
patients, i.e., women aged 45 or less, treated with neoadjuvant
CT, we observed that lower values of BMI were associated with
longer OS, along with non-TN molecular subtype and adjuvant
RT.12 However, this latter study population included a limited
number of HER2-positive cases, i.e. 19/45, while the vast
majority of tumors expressed hormone receptors, i.e. 52/86. In
addition, differences in treatment outcomes may also be driven
by a more aggressive behavior, which is well documented in
women diagnosed at a young age.18,19
Our study has some limitations. Firstly, the observational,
retrospective design increases the chance for bias and con-
founding, which we attempted to contain by statistical meth-
ods, e.g. data stratification and adjustment in multivariate
models. Secondarily, missing data of potentially relevant varia-
bles have limited our ability to compare findings from this
study to those from the TURANDOT, as well exemplified by
the lack of information on menopausal status, although we con-
sidered age as a proxy variable with no significant results.
Thirdly, the sample size is limited, still, potentially acceptable
given the “operating” nature of our setting, i.e. a real world set-
ting, and the difficulties related to the conduct of such a study
in a real world population.
Our study also has strengths. Current knowledge on the role
of BMI on treatment outcomes in MBC is scant and the extent
to which the available evidence from the early setting may be
translated to these patients is openly questionable. Further-
more, the interest of the scientific community towards life-style
related factors with an impact on cancer is fuelled by their
modifiable nature, which may translate into improved out-
comes in breast and other cancers.20-22 In this view, investigat-
ing the role of BMI on treatment outcomes of HER2-negative
metastatic breast cancer patients may appear particularly
appealing, since this disease is still considered incurable.23 Our
main finding is represented by the impact of BMI in the sub-
group of patients with TN disease, with reflections in terms of
both DCR and survival. In multivariate Cox models, the addi-
tion of an interaction terms for BMI and molecular subgroups
yielded significant results. However, given the hypothesis-gen-
erating nature of our study and the limited size of patients with
TN MBC (N:43), our findings warrant confirmation in ade-
quately sized, prospective studies of HER2-negative MBC
patients treated with first-line paclitaxel and bevacizumab.
When designing such studies, researchers will hopefully con-
sider difficulties stemming from the current limitations of the
inherent literature, not only from a quantitative, but also from
Figure 3. Overall Survival by number of metastatic sites (A) and length of progression free survival in the overall study population (N: 196).
Table 4. Multivariate analysis of factors impacting treatment outcomes in the overall study population (N:196).
Progression-free Survival p value Overall Survival p value
Variables HR (CI95%) p value HR (CI95%) p value
Molecular Subtype TN vs ER/PgR pos 1.57 (1.07-2.33) 0.02 2.82 (1.61-5.18) <0.0001
PFS 1st line <12 vs 12 months — — 2.08 (1.23-3.51) 0.006
N. of met sites >2 vs 2 — — 6.50 (3.61-11.71) <0.0001
PFS, progression-free survival; OS, overall survival; HR, Hazard Ratio; CI95%, confidence interval; ER, estrogen receptor; PgR, progesterone receptor.
Interaction BMI/molsub OS pD0.008.
Interaction BMI/molsub PFS pD0.002.
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a qualitative standpoint. Indeed, comparing evidence from
studies differing significantly by design, patient-/disease charac-
teristics and administered treatment may be misleading and
methodologically incorrect.
In conclusions, in this multicentric, observational study of
HER2-negative MBC patients treated with paclitaxel and beva-
cizumab in first-line we found evidence of the role of BMI on
DCR, PFS and OS in the subgroup of TN patients. This finding
is of difficult interpretation, given the limitations of the cur-
rently available evidence from our research group and from
other researchers. Given the still incurable character of the dis-
ease of interest and the interest towards BMI and, more gener-
ally, factors related to life-style with a potential impact on
treatment outcomes, further studies are warranted to confirm
our findings and allow a deeper comprehension of the underly-
ing mechanisms.
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